These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34254870)

  • 21. Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma.
    Chen X; Zheng Y; Zhang Q; Chen Q; Chen Z; Wu D
    J Nanobiotechnology; 2024 May; 22(1):264. PubMed ID: 38760771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
    Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glioblastoma vs temozolomide: can the red queen race be won?
    Arora A; Somasundaram K
    Cancer Biol Ther; 2019; 20(8):1083-1090. PubMed ID: 31068075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antioxidant responses related to temozolomide resistance in glioblastoma.
    Campos-Sandoval JA; Gómez-García MC; Santos-Jiménez JL; Matés JM; Alonso FJ; Márquez J
    Neurochem Int; 2021 Oct; 149():105136. PubMed ID: 34274381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lnc-TALC promotes O
    Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
    Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
    Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
    Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.
    Yang B; Ma YB; Chu SH
    Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.
    Salvatori L; Malatesta S; Illi B; Somma MP; Fionda C; Stabile H; Fontanella RA; Gaetano C
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response.
    Hombach-Klonisch S; Mehrpour M; Shojaei S; Harlos C; Pitz M; Hamai A; Siemianowicz K; Likus W; Wiechec E; Toyota BD; Hoshyar R; Seyfoori A; Sepehri Z; Ande SR; Khadem F; Akbari M; Gorman AM; Samali A; Klonisch T; Ghavami S
    Pharmacol Ther; 2018 Apr; 184():13-41. PubMed ID: 29080702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1.
    Wang S; Chen C; Li J; Xu X; Chen W; Li F
    J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.
    Liu T; Li A; Xu Y; Xin Y
    Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in research and development of temozolomide brain-targeted preparations: a review.
    Yang J; Xu Y; Fu Z; Chen J; Fan W; Wu X
    J Drug Target; 2023 Feb; 31(2):119-133. PubMed ID: 36039767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
    Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
    Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
    Wang J; Zuo J; Wahafu A; Wang MD; Li RC; Xie WF
    CNS Neurosci Ther; 2020 Mar; 26(3):297-308. PubMed ID: 31318172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glioblastoma stem cells resistant to temozolomide-induced autophagy.
    Fu J; Liu ZG; Liu XM; Chen FR; Shi HL; Pangjesse CS; Ng HK; Chen ZP
    Chin Med J (Engl); 2009 Jun; 122(11):1255-9. PubMed ID: 19567133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics.
    Grek CL; Sheng Z; Naus CC; Sin WC; Gourdie RG; Ghatnekar GG
    Curr Opin Pharmacol; 2018 Aug; 41():79-88. PubMed ID: 29803991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.